Join
Live feed
·
PRReleasevia Quantisnow
Altimmune Inc. logo

Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers

ByQuantisnow·Wall Street's wire, on your screen.
ALT· Altimmune Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALT (Altimmune Inc.) and more on Quantisnow.